Discovering novel direct acting antiviral agents for HBV using in silico screening.

Yoshiki Murakami, Michiyo Hayakawa, Yoshihiko Yano, Toshihito Tanahashi, Masaru Enomoto, Akihiro Tamori, Norifumi Kawada, Mitsuo Iwadate, Hideaki Umeyama

Index: Biochem. Biophys. Res. Commun. 456(1) , 20-8, (2015)

Full Text: HTML

Abstract

The treatments for chronic hepatitis B (CHB) are interferon and nucleoside analogues reverse transcriptase (RT) inhibitors. Because both treatments are less than ideal, we conducted to identify novel anti-viral agents for HBV-reverse transcriptase (HBV-RT). We determined the ligand-binding site of the HBV-RT by conducting a homological search of the amino acid sequence and then we also determined not only structural arrangement of the target protein but the target protein-binding site of the ligand using known protein-ligand complexes in registered in the protein data bank (PDB). Finally we simulated binding between the ligand candidates and the HBV-RT and evaluated the degree of binding (in silico screening). PXB cells derived from human-mouse chimeric mouse liver, infected with HBV were administrated with the candidates, and HBVDNA in the culture medium was monitored by realtime qPCR. Among compounds from the AKosSamples database, twelve candidates that can inhibit RT were also identified, two of which seem to have the potential to control HBV replication in vitro. Copyright © 2014 Elsevier Inc. All rights reserved.